ライフサイエンスコーパス: portosystemic

1 containing a migrated stent and facilitates portosystemic bypass and portal anastomosis.

2 nt, the liver transplant was completed under portosystemic bypass.

3 paraumbilical vein, and number of collateral portosystemic channels.

4 nd diameter of paraumbilical vein, number of portosystemic collateral channels and diameter of portal

5 We analysed the number and type of portosystemic collateral channels in respect of age, sex

6 der paraumbilical veins and higher number of portosystemic collateral channels.

7 paraumbilical vein (PUV) and the presence of portosystemic collateral shunts and their relationship w

8 -Stage Liver Disease score (P < 0.001), more portosystemic collaterals (P = 0.01) and splenomegaly (P

9 viates portal hypertension (PH), severity of portosystemic collaterals and mesenteric angiogenesis, i

10 hnic hyperemia, increased portal inflow, and portosystemic collaterals formation, which may induce le

11 Gastroesophageal varices are portosystemic collaterals formed due to portal hypertens

12 rtal hypertension (shunting of blood through portosystemic collaterals) and hepatic insufficiency res

13 rtal hypertension (shunting of blood through portosystemic collaterals) and hepatic insufficiency tha

14 rtal hypertension (shunting of blood through portosystemic collaterals) and hepatic insufficiency.

15 mong gastroesophageal varices, splenomegaly, portosystemic collaterals, history of ascites, or platel

16 hyperdynamic circulation, angiogenesis, and portosystemic collaterals.

17 CBs may be targeted in the control of PH and portosystemic collaterals.

18 ver, TIPS is associated with higher rates of portosystemic encephalopathy and possibly higher costs.

19 d evidence of portal hypertension (recurrent portosystemic encephalopathy and variceal hemorrhage) in

20 Portosystemic encephalopathy is a consequence of both po

21 Portosystemic encephalopathy is a consequence of both po

22 Another complication of cirrhosis, portosystemic encephalopathy, is a consequence of both p

23 ty-two patients with cirrhosis underwent the Portosystemic Encephalopathy-Syndrome-Test yielding the

24 H-related complications, such as ascites and portosystemic encephalopathy.

25 lications: variceal hemorrhage, ascites, and portosystemic encephalopathy.

26 lications: variceal hemorrhage, ascites, and portosystemic encephalopathy.

27 inical success was defined as a reduction of portosystemic gradient (PSG) and resolution of RA.

28 esults were compared, which included initial portosystemic gradient and Doppler measurements of blood

29 In 100 consecutive subjects, mean portosystemic gradient decreased from 24 to 11 mm Hg (me

30 eceptor were tested, and measurements of the portosystemic gradient were used to determine Gabsorp an

31 Differences in mean portosystemic gradients (PSGs) were evaluated by using t

32 Portosystemic pressure gradient (28 vs 11 cm H(2)O; P <

33 The portosystemic pressure gradient (PSG) was decreased to n

34 venography, which can be used to measure the portosystemic pressure gradient (PSPG) to identify TIPS-

35 A portosystemic pressure gradient of > or =12 mm Hg is not

36 ination, portography with measurement of the portosystemic pressure gradient.

37 (77%) with and seven (23%) without elevated portosystemic pressure gradients.

38 r, eNOS (-/-) mice did develop a substantial portosystemic shunt (0.33% +/- 0.005% vs 84.53% +/- 0.19

39 2 +/- 0.003 vs 0.227 +/- 0.005 mL/min/g) and portosystemic shunt (0.47% +/- 0.01% vs 84.13% +/- 0.09%

40 ophylaxis group was less likely to require a portosystemic shunt (6% vs 15%, p < 0.001) with no diffe

41 Congenital extrahepatic portosystemic shunt (CEPS) or Abernethy malformation is

42 A preemptive transjugular intrahepatic portosystemic shunt (p-TIPS) has been shown to improve s

43 ated by the presence of congenitally present portosystemic shunt (PSS), which resulted in markedly el

44 l and biochemical features of the congenital portosystemic shunt (PSS).

45 150 min liver warm ischemia with or without portosystemic shunt (splenic-caval shunt).

46 Transjugular intrahepatic portosystemic shunt (TIPS) and surgical distal splenoren

47 lity and safety of transjugular intrahepatic portosystemic shunt (TIPS) as a treatment for BCS with d

48 thoracentesis and transjugular intrahepatic portosystemic shunt (TIPS) as second-line therapeutic op

49 ter placement of a transjugular intrahepatic portosystemic shunt (TIPS) correlates with the absence o

50 ailure (ELF) after transjugular intrahepatic portosystemic shunt (TIPS) creation in patients with cir

51 Background Transjugular intrahepatic portosystemic shunt (TIPS) creation is an accepted treat

52 d complications of transjugular intrahepatic portosystemic shunt (TIPS) creation performed by using a

53 ents who underwent transjugular intrahepatic portosystemic shunt (TIPS) creation, regardless of left

54 Background Transjugular intrahepatic portosystemic shunt (TIPS) dysfunction in patients with

55 and bare stent in transjugular intrahepatic portosystemic shunt (TIPS) for cirrhotic portal hyperten

56 ibe the results of transjugular intrahepatic portosystemic shunt (TIPS) for the management of VOD aft

57 Recently, transjugular intrahepatic portosystemic shunt (TIPS) has been compared with ET in

58 the placement of a transjugular intrahepatic portosystemic shunt (TIPS) has been reported in up to 10

59 on human patients, transjugular intrahepatic portosystemic shunt (TIPS) has been worldwide considered

60 ients treated with transjugular intrahepatic portosystemic shunt (TIPS) have lower rebleeding rates c

61 Implantation of a transjugular intrahepatic portosystemic shunt (TIPS) improves survival in patients

62 s, and efficacy of transjugular intrahepatic portosystemic shunt (TIPS) in a series of patients with

63 Transjugular intrahepatic portosystemic shunt (TIPS) in patients with portal hyper

64 cacy and safety of transjugular intrahepatic portosystemic shunt (TIPS) in this population are unknow

65 opathy (HE) after Trans-jugular intrahepatic portosystemic shunt (TIPS) is a common clinical problem.

66 The transjugular intrahepatic portosystemic shunt (TIPS) is an important treatment for

67 Transjugular intrahepatic portosystemic shunt (TIPS) is now a standard for the tre

68 Transjugular intrahepatic portosystemic shunt (TIPS) is one of the main treatment

69 Transjugular intrahepatic portosystemic shunt (TIPS) is performed to treat some co

70 Transjugular intrahepatic portosystemic shunt (TIPS) is used in the management of

71 ansplantation, and transjugular intrahepatic portosystemic shunt (TIPS) on patient selection and outc

72 The effects of transjugular intrahepatic portosystemic shunt (TIPS) on portal hemodynamics, esoph

73 ty and efficacy of transjugular intrahepatic portosystemic shunt (TIPS) performed semiemergently and

74 Elective transjugular intrahepatic portosystemic shunt (TIPS) placement can worsen cognitiv

75 disease underwent transjugular intrahepatic portosystemic shunt (TIPS) placement for control of vari

76 hosis and ascites, transjugular intrahepatic portosystemic shunt (TIPS) placement improves control of

77 on with or without transjugular intrahepatic portosystemic shunt (TIPS) placement in patients who are

78 Transjugular intrahepatic portosystemic shunt (TIPS) placement is effective in the

79 w before and after transjugular intrahepatic portosystemic shunt (TIPS) placement.

80 nts undergoing the transjugular intrahepatic portosystemic shunt (TIPS) procedure in patient groups w

81 cations related to transjugular intrahepatic portosystemic shunt (TIPS) stents found in the portal ve

82 converting failed transjugular intrahepatic portosystemic shunt (TIPS) to distal splenorenal shunt (

83 canalization (PVR)-transjugular intrahepatic portosystemic shunt (TIPS) to potentiate LT.

84 ognosis of salvage transjugular intrahepatic portosystemic shunt (TIPS) using covered stents for refr

85 Additional transjugular intrahepatic portosystemic shunt (TIPS) was created to facilitate the

86 The transjugular intrahepatic portosystemic shunt (TIPS) was developed in the 1980s fo

87 ble on the role of transjugular intrahepatic portosystemic shunt (TIPS) with covered stents in patien

88 ant and five had a transjugular intrahepatic portosystemic shunt (TIPS).

89 ainly treated with transjugular intrahepatic portosystemic shunt (TIPS).

90 atients undergoing transjugular intrahepatic portosystemic shunt (TIPS).

91 for creation of a transjugular intrahepatic portosystemic shunt (TIPS).

92 paracentesis, and transjugular intrahepatic portosystemic shunt (TIPS)], but refractory hydrothorax

93 ng procedures (upper endoscopy, transjugular portosystemic shunt [TIPS], hemodialysis, and liver tran

94 traindications of transjugular intra-hepatic portosystemic shunt and for the treatment of gastro-esop

95 evaluate race as a predictor of undergoing a portosystemic shunt and LT and of dying in the hospital.

96 creased patency at transjugular intrahepatic portosystemic shunt creation.

97 Ppv), abdominal aortic blood flow (Qao), and portosystemic shunt determined 2 weeks later.

98 Portosystemic shunt enhances the tolerance of liver to w

99 Transjugular intrahepatic portosystemic shunt has become an accepted intervention

100 paracentesis with transjugular intrahepatic portosystemic shunt in the management of refractory asci

101 Although transjugular intrahepatic portosystemic shunt insertion (TIPS) is indicated for th

102 A transjugular intrahepatic portosystemic shunt is indicated when control of the ref

103 vein embolization, transjugular intrahepatic portosystemic shunt placement, balloon retrograde transv

104 beta-blockers and transjugular intrahepatic portosystemic shunt placement.

105 The transjugular intrahepatic portosystemic shunt procedure is an effective interventi

106 who underwent the transjugular intrahepatic portosystemic shunt procedure.

107 ation or undergoing transvenous intrahepatic portosystemic shunt procedures.

108 A modified transjugular intrahepatic portosystemic shunt puncture set was introduced from the

109 to the systemic circulation, which is called portosystemic shunt syndrome.

110 previously placed transjugular intrahepatic portosystemic shunt underwent successful liver transplan

111 andomized trial of transjugular intrahepatic portosystemic shunt using covered stents and another pil

112 A transjugular intrahepatic portosystemic shunt was created in 14 young swine (weigh

113 tes, the adjusted odds ratios of receiving a portosystemic shunt were 0.37 (95% CI: 0.27-0.51) and 0.

114 raindication for a transjugular intrahepatic portosystemic shunt who received either device implantat

115 l stenosis and the presence of a spontaneous portosystemic shunt whose successful endovascular treatm

116 ugs+endoscopy, the placement of transjugular portosystemic shunt within 72 hours of admission (pre-em

117 Two patients had an extrahepatic portosystemic shunt, 17 had a portacaval shunt [subdivid

118 band ligation and transjugular intrahepatic portosystemic shunt, almost every acute variceal bleed c

119 us-1, previous LT, transjugular intrahepatic portosystemic shunt, and acute dialysis at LT.

120 e hepatocytes after liver warm ischemia with portosystemic shunt, compared with liver ischemia withou

121 ve been treated by transjugular intrahepatic portosystemic shunt, surgical exploration, or peritoneov

122 ter placement of a transjugular intrahepatic portosystemic shunt.

123 erance of liver to warm ischemia injury with portosystemic shunt.

124 is increase was significantly reversed after portosystemic shunt.

125 be referred for to transjugular intrahepatic portosystemic shunt.

126 oes not preclude the creation of nonsurgical portosystemic shunt.

127 ion or stenosis and the presence of a patent portosystemic shunt.

128 ssion (pre-emptive transjugular intrahepatic portosystemic shunt: p-TIPS) increases the survival of h

129 ic artery flow, mesenteric vascular density, portosystemic shunting (PSS), intrahepatic angiogenesis,

130 ility, before/after transvenous intrahepatic portosystemic shunting (TIPS), and before/after yogurt t

131 catheter-directed thrombolysis, transjugular portosystemic shunting (TIPS), and liver transplantation

132 asty/thrombolysis, transjugular intrahepatic portosystemic shunting (TIPS), and orthotopic liver tran

133 th vehicle, JWH-015 significantly alleviated portosystemic shunting and mesenteric vascular density i

134 ement therapy, and transjugular intrahepatic portosystemic shunting are discussed.

135 Liver disease or portosystemic shunting enhances th e sensitivity to endo

136 iography, which disclosed virtually complete portosystemic shunting in Fut2(-/-)(high) mice, discrete

137 c shunting in Fut2(-/-)(high) mice, discrete portosystemic shunting in Fut2(-/-)(low) mice, and no sh

138 ler hepatocyte size is the result of massive portosystemic shunting in null animals.

139 scularization with transjugular intrahepatic portosystemic shunting may also be considered for transp

140 scularization with transjugular intrahepatic portosystemic shunting may be considered for selected pa

141 t2(-/-) mice is dominated by consequences of portosystemic shunting resulting in microcirculatory dis

142 with subsequent guidewire snaring to perform portosystemic shunting via femoral access.

143 Portosystemic shunting was demonstrated by portal angiog

144 Portosystemic shunting was shown by radiological methods

145 be successfully used as a bridge to surgical portosystemic shunting, as well as liver transplantation

146 modalities such as transjugular intrahepatic portosystemic shunting, hemodialysis, and in some cases,

147 amics, presence of CB receptors, severity of portosystemic shunting, mesenteric vascular density, vas

148 al indications for transjugular intrahepatic portosystemic shunting, such as those with refractory as

149 Congenital portosystemic shunts (CPSS) are rare vascular malformati

150 rum samples from dogs with either congenital portosystemic shunts (cPSS, n = 24) or high serum liver

151 lar in preclinical research, have congenital portosystemic shunts (PSS) that allow venous blood to en

152 urements, including portal pressure (PP) and portosystemic shunts (PSS), and collected tissues for hi

153 Spontaneous portosystemic shunts (SPSSs) are common among patients w

154 Large spontaneous portosystemic shunts (SPSSs) have been previously sugges

155 The impact of spontaneous portosystemic shunts (SPSSs) on natural history of cirrh

156 d to the consequent formation of spontaneous portosystemic shunts (SPSSs), leading to complications r

157 Transjugular intrahepatic portosystemic shunts (TIPS) are a recent innovation in t

158 Transjugular intrahepatic portosystemic shunts (TIPS) are sometimes used to reduce

159 te the efficacy of transjugular intrahepatic portosystemic shunts (TIPS) for the treatment of chronic

160 after creation of transjugular intrahepatic portosystemic shunts (TIPS) has been attributed to hemol

161 re of infection of transjugular intrahepatic portosystemic shunts (TIPS) has not been described previ

162 Transjugular intrahepatic portosystemic shunts (TIPS) have widened the use of port

163 ts with the use of transjugular intrahepatic portosystemic shunts (TIPS) in the treatment of these pa

164 Transjugular intrahepatic portosystemic shunts (TIPS) is a second-line treatment b

165 ectasia (GVE), to transjugular intrahepatic portosystemic shunts (TIPS) is not known.

166 Transjugular intrahepatic portosystemic shunts (TIPS) lower portal pressure and ha

167 Transjugular intrahepatic portosystemic shunts (TIPS) may worsen liver function an

168 ver the ability of transjugular intrahepatic portosystemic shunts (TIPS) to increase survival times o

169 ver the ability of transjugular intrahepatic portosystemic shunts (TIPS) to increase survival times o

170 linical utility of transjugular intrahepatic portosystemic shunts (TIPS) vis-a-vis total paracentesis

171 (CT) angiograms of transjugular intrahepatic portosystemic shunts (TIPS), helical CT angiography was

172 ing the patency of transjugular intrahepatic portosystemic shunts (TIPS).

173 s alternative treatment options to operative portosystemic shunts and devascularization procedures.

174 Despite these innovations, portosystemic shunts and esophagogastric devascularizati

175 Large spontaneous portosystemic shunts are associated significantly with m

176 Transjugular intrahepatic portosystemic shunts are frequently used in patients wit

177 The indications for and the results of portosystemic shunts done in the authors' institution si

178 Spontaneous portosystemic shunts greater than 10 mm in diameter, ide

179 ocumented the frequency of large spontaneous portosystemic shunts in patients with moderate or severe

180 Transjugular intrahepatic portosystemic shunts may be helpful in the treatment of

181 Conclusion The presence of spontaneous portosystemic shunts on CT images in patients with cirrh

182 outflow obstruction classically treated with portosystemic shunts or liver transplantation.

183 Early transjugular intrahepatic portosystemic shunts placed in highly selected patients

184 Models described in rats using portosystemic shunts to achieve total ischemia have been

185 lume paracenteses, transjugular intrahepatic portosystemic shunts, and implanted drainage devices.

186 All extrahepatic portosystemic shunts, H-type portal-caval, portohepatic,

187 g and placement of transjugular intrahepatic portosystemic shunts, have improved preoperative assessm

188 Five had variceal bleeding, and 2 had portosystemic shunts.

189 , liver transplants, choledocholithiasis, or portosystemic shunts.

190 ctive placement of transjugular intrahepatic portosystemic shunts.

191 or insertion of a transjugular intrahepatic portosystemic stent shunt (TIPS).

192 ctively treated by transjugular intrahepatic portosystemic stent shunt (TIPS).

193 en a small covered transjugular intrahepatic portosystemic stent-shunt (TIPS) (8 mm; n = 90), or medi

194 udy was to compare transjugular intrahepatic portosystemic stent-shunt (TIPSS) with variceal band lig

195 de, but fluoroscopically placed intrahepatic portosystemic stents have recently been used with increa